| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
26 |
S5 |
p. v_vi
|
artikel
|
| 2 |
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
|
Ducreux, M.
|
|
|
26 |
S5 |
p. v56-v68
|
artikel
|
| 3 |
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
|
Parker, C.
|
|
|
26 |
S5 |
p. v69-v77
|
artikel
|
| 4 |
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
|
Fizazi, K.
|
|
|
26 |
S5 |
p. v133-v138
|
artikel
|
| 5 |
Central venous access in oncology: ESMO Clinical Practice Guidelines †
|
Sousa, B.
|
|
|
26 |
S5 |
p. v152-v168
|
artikel
|
| 6 |
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
|
Eichhorst, B.
|
|
|
26 |
S5 |
p. v78-v84
|
artikel
|
| 7 |
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
|
Dummer, R.
|
|
|
26 |
S5 |
p. v126-v132
|
artikel
|
| 8 |
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
|
Tilly, H.
|
|
|
26 |
S5 |
p. v116-v125
|
artikel
|
| 9 |
Editorial board
|
|
|
|
26 |
S5 |
p. i-ii
|
artikel
|
| 10 |
ESMO Guidelines Committee
|
|
|
|
26 |
S5 |
p. v_v
|
artikel
|
| 11 |
ESMO Guidelines Committee Disclosures
|
|
|
|
26 |
S5 |
p. v178-v179
|
artikel
|
| 12 |
Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
|
Robak, T.
|
|
|
26 |
S5 |
p. v100-v107
|
artikel
|
| 13 |
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
|
Baas, P.
|
|
|
26 |
S5 |
p. v31-v39
|
artikel
|
| 14 |
Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up†
|
Peterson, D.E.
|
|
|
26 |
S5 |
p. v139-v151
|
artikel
|
| 15 |
Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
|
d'Amore, F.
|
|
|
26 |
S5 |
p. v108-v115
|
artikel
|
| 16 |
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
|
Vannucchi, A.M.
|
|
|
26 |
S5 |
p. v85-v99
|
artikel
|
| 17 |
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
|
Senkus, E.
|
|
|
26 |
S5 |
p. v8-v30
|
artikel
|
| 18 |
Table of Contents
|
|
|
|
26 |
S5 |
p. iv
|
artikel
|
| 19 |
The ESMO Guidelines Committee would like to publish the following corrections to manuscripts published in 2014
|
|
|
|
26 |
S5 |
p. v174-v177
|
artikel
|
| 20 |
The ESMO guideline strategy: an identity statement and reflections on improvement
|
Pentheroudakis, G.
|
|
|
26 |
S5 |
p. v1-v7
|
artikel
|
| 21 |
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
|
Girard, N.
|
|
|
26 |
S5 |
p. v40-v55
|
artikel
|
| 22 |
Title page
|
|
|
|
26 |
S5 |
p. iii
|
artikel
|
| 23 |
Treatment of dyspnoea in advanced cancer patients: ESMO Clinical Practice Guidelines †
|
Kloke, M.
|
|
|
26 |
S5 |
p. v169-v173
|
artikel
|
Tijdschrift beschrijving